---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-016887"
form_type: "8-K"
ticker: "ANTX"
cik: "0001880438"
company_name: "AN2 Therapeutics, Inc."
filed_at: "2022-08-11T23:59:59+00:00"
generated_at: "2026-06-24T01:08:57.482162+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# AN2 Therapeutics reports Q2 2022 cash of $115.8M, updates on epetraborole trials

## Summary
- Cash, cash equivalents and investments $115.8M at June 30, 2022; sufficient to fund operations through mid-2024.
- Enrolling U.S. patients in Phase 2/3 trial of epetraborole for treatment-refractory MAC lung disease; topline Phase 2 results expected mid-2023.
- Completed Phase 1 PK/safety study in Japan; gained PMDA alignment on microbiological primary endpoint for potential registration.
- Maggie FitzPatrick appointed to Board of Directors; she previously led public affairs at Johnson & Johnson.
- R&D and G&A expenses increased due to higher trial activity and expanded post-IPO operations.

## SEC filing metadata
- accession: 0000950170-22-016887
- form_type: 8-K
- ticker: ANTX
- cik: 0001880438
- company_name: AN2 Therapeutics, Inc.
- filed_at: 2022-08-11T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1880438/000095017022016887/0000950170-22-016887-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1880438/000095017022016887/antx-20220811.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-016887
- JSON: https://secwatch.observer/filing/0000950170-22-016887.json
- Plain text: https://secwatch.observer/filing/0000950170-22-016887.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.